ORBUSNEICH (06929.HK): Lau Kwai Ching appointed Co-Chief Executive Officer, management changes effective 17 August
NewTimeSpace News: On 17 August 2026, OrbusNeich Medical Group Holdings Limited (stock code: 06929) announced changes to its chief officers, effective 17 August 2026. Executive Director Ms. Lau Kwai Ching has been appointed Co-Chief Executive Officer, jointly holding the position with Chairman Mr. Chin Wing Han, and will cease to serve as Chief Operating Officer.
Meanwhile, Executive Director Mr. Chan Wing Shing has been appointed Chief Operating Officer, ceasing to serve as Chief Financial Officer and Company Secretary; Ms. Chan Man Ying has been appointed Chief Financial Officer and Company Secretary. Effective 17 August 2026, the annual base salary of Ms. Lau for all positions in the Group is HKD 4,636,320 and that of Mr. Chan is HKD 3,554,640, with both entitled to discretionary bonuses and employer retirement benefit scheme contributions.
According to the announcement, Ms. Lau, aged 52, has over 27 years of experience in legal, business operations and management, and is the spouse of Chairman Mr. Chin Wing Han; Mr. Chan, aged 45, has approximately 23 years of experience in audit, accounting and corporate finance, and is a practicing senior accountant in Hong Kong, Washington State and Delaware, as well as a CFA charterholder; Ms. Chan, aged 51, has over 28 years of experience in finance, accounting, audit and corporate management.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- ORBUSNEICH (06929.HK): First Patient Enrolled in Pivotal Japanese Clinical Trial for Self-developed Drug-Coated Balloon
- Harvest CSI 300 ESG Leaders Index ETF (03108.HK) Fell 3.72% in Afternoon Trade, Latest NAV at HKD 10.555
- Harvest CSI 300 ESG Leaders Index ETF (03108.HK) Falls 2.15% in Afternoon Trade, Turnover at HKD 1.8871 Million
- Harvest CSI 300 ESG Leaders Index ETF (03108.HK) Rises 2.63% in Afternoon Trade, Latest Price at HKD 10.920
- Harvest CSI 300 ESG Leaders Index ETF (03108.HK) Rises 2.09% to HKD 11.220